NASDAQ:ENVB Enveric Biosciences Q2 2026 Earnings Results & Report $1.44 -0.08 (-4.95%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$1.44 0.00 (0.00%) As of 11/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Enveric Biosciences reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$0.76. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeAfter Market Closes Enveric Biosciences EPS ResultsActual EPS-$0.76Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate4 of last 4 quartersEnveric Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Enveric Biosciences Q2 2026 Earnings FAQ Did Enveric Biosciences beat earnings estimates for Q2 2026? Enveric Biosciences (NASDAQ:ENVB) reported earnings of -$0.76 per share for Q2 2026. The report was announced on Friday, August 14, 2026. Enveric Biosciences Earnings HeadlinesEnveric Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14 at 2:18 PM | marketscreener.comMEnveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate UpdateNovember 13, 2026 | businesswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)Enveric Biosciences reports favorable brain activity data for lead psychiatric drug candidateNovember 4, 2026 | msn.comEnveric Biosciences Moves Lead Neuroplastogenic Candidate Closer To Clinical TestingOctober 22, 2026 | rttnews.comEnveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET StudiesOctober 21, 2026 | marketscreener.comMSee More Enveric Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email. Email Address About Enveric BiosciencesEnveric Biosciences (NASDAQ:ENVB) is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety. The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines. Enveric expanded into psychedelic-inspired drug discovery through its 2021 acquisition of MagicMed Industries. It is headquartered in Naples, Florida.View Enveric Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.